SCHEMBL6508169

SCHEMBL6508169

C[Si](C)(C)CCC(=O)N1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.59
CASP6 P55212 1/20 0.59
MAPT P10636 11/20 0.50
LMNA P02545 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GAA P10253 5/20 0.49
ALDH1A1 P00352 4/20 0.49
ALOX12 P18054 2/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTR1A P08908 1/20 0.47
HTR7 P34969 1/20 0.47
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAD52 P43351 1/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADRA2C P18825 1/20 0.46
PTK2B Q14289 1/20 0.46
ESR2 Q92731 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994240 0.82 GFER (0.61) GFERCASP6MAPTLMNANPSR1
SCHEMBL6506583 0.81 MAPT (0.66) MAPTLMNANPSR1ALDH1A1CYP2C19
SCHEMBL1813106 0.80 GFER (0.68) GFERCASP6MAPTLMNAGAA
SCHEMBL8230640 0.80 GFER (0.59) GFERCASP6MAPTLMNANPSR1
SCHEMBL15650594 0.79 GFER (0.65) GFERCASP6MAPTLMNANPSR1
SCHEMBL188832 0.79 AKR1C3 (0.65) GFERCASP6MAPTLMNANPSR1
SCHEMBL23911877 0.77 GLA (0.56) GFERCASP6MAPTLMNANPSR1
SCHEMBL8230222 0.77 MAPT (0.67) GFERCASP6MAPTLMNAGAA
SCHEMBL13153240 0.77 GFER (0.62) GFERCASP6MAPTLMNANPSR1
SCHEMBL2387391 0.77 GFER (0.62) GFERCASP6MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2005-02-10 US disclosed
EP-1309594-B1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2004-12-15 EP disclosed
US-6794382-B2 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT SANOFI-SYNTHELABO (FR) 2004-09-21 US disclosed
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2003-10-30 US disclosed
CN-1446218-A Benzimidazole derivatives, their preparation and their therapeutic use SANOFI SYNTHELABO (FR) 2003-10-01 CN disclosed
EP-1309594-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2003-05-14 EP disclosed
WO-2002012239-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-SYNTHELABO (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, CYP3A7, HDAC7 GFER 1623/4885CASP6 1403/4885MAPT 4389/4885
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, HRH4, CBR1 GFER 1857/4885CASP6 1387/4885MAPT 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.